Physician profile
Massoud Rasooli
NPI 1720587082
$2,911.54
in general payments reported to CMS, 2019-2025
18 companies · $1,514 in 2025
The $1,514 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $110 · 2022: $142 · 2023: $416 · 2024: $731 · 2025: $1,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,660.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $776.81 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $638.11 | 2023-2025 | Entyvio |
| Celgene Corporation | $272.66 | 2022-2024 | Zeposia |
| Vivus LLC | $271.47 | 2021-2024 | Qsymia, Pancreaze |
| Ardelyx, INC. | $230.43 | 2025 | Ibsrela |
| Redhill Biopharma INC. | $170.96 | 2021-2025 | Talicia, Movantik, Aemcolo |
| Ironwood Pharmaceuticals, INC | $120.33 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.11 | 2025 | Xifaxan |
| Genzyme Corporation | $59.74 | 2025 | |
| Phathom Pharmaceuticals, INC. | $57.08 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $51.57 | 2024-2025 | Suflave, Sutab |
| Madrigal Pharmaceuticals | $47.25 | 2025 | Rezdiffra |
| Pfizer INC. | $46.18 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $32.76 | 2025 | Dupixent |
| Aimmune Therapeutics, INC. | $24.11 | 2025 | Zenpep |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $16.36 | 2025 | Tremfya |
| Fresenius Kabi USA, LLC | $15.75 | 2023 | Smoflipid |
| Lilly USA, LLC | $13.86 | 2025 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Massoud Rasooli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.